Tags

Type your tag names separated by a space and hit enter

Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Am J Epidemiol 2010; 171(5):571-82AJ

Abstract

The authors conducted a nested case-control study of serum inflammatory markers and risk of symptomatic benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH (n = 676) was defined as treatment, report of 2 International Prostate Symptom Score (IPSS) values >14, or 2 increases of > or = 5 from baseline values with at least one value > or = 12. Controls (n = 683) were men who reported no BPH treatment or IPSS values >7 over the 7-year trial. Baseline serum was analyzed for C-reactive protein, tumor necrosis factor alpha (monomer), soluble tumor necrosis factor receptors I and II (sTNF-RI and sTNF-RII), interleukin 6, and interferon gamma. Controlled for age and race, a high C-reactive protein concentration was associated with increased BPH risk (for quartile 4 vs. quartile 1, odds ratio (OR) = 1.40, 95% confidence interval (CI): 1.04, 1.88); this was attenuated after control for body mass index (OR = 1.30, 95% CI: 0.95, 1.75). Low sTNF-RII and high interleukin 6 concentrations were associated with increased BPH risk (for quartile 4 vs. quartile 1, sTNF-RII: OR = 0.61, 95% CI: 0.46, 0.82; interleukin 6: OR = 1.79, 95% CI: 1.32, 2.42); these associations were only in men aged <65 years. Results suggest that systemic inflammation or lower levels of soluble receptors that bind inflammatory cytokines increase BPH risk.

Authors+Show Affiliations

Schenk, Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. jschenk@fhcrc.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

20142396

Citation

Schenk, Jeannette M., et al. "Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial." American Journal of Epidemiology, vol. 171, no. 5, 2010, pp. 571-82.
Schenk JM, Kristal AR, Neuhouser ML, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2010;171(5):571-82.
Schenk, J. M., Kristal, A. R., Neuhouser, M. L., Tangen, C. M., White, E., Lin, D. W., ... Thompson, I. M. (2010). Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. American Journal of Epidemiology, 171(5), pp. 571-82. doi:10.1093/aje/kwp406.
Schenk JM, et al. Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial. Am J Epidemiol. 2010 Mar 1;171(5):571-82. PubMed PMID: 20142396.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. AU - Schenk,Jeannette M, AU - Kristal,Alan R, AU - Neuhouser,Marian L, AU - Tangen,Catherine M, AU - White,Emily, AU - Lin,Daniel W, AU - Kratz,Mario, AU - Thompson,Ian M, Y1 - 2010/02/08/ PY - 2010/2/10/entrez PY - 2010/2/10/pubmed PY - 2010/4/1/medline SP - 571 EP - 82 JF - American journal of epidemiology JO - Am. J. Epidemiol. VL - 171 IS - 5 N2 - The authors conducted a nested case-control study of serum inflammatory markers and risk of symptomatic benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH (n = 676) was defined as treatment, report of 2 International Prostate Symptom Score (IPSS) values >14, or 2 increases of > or = 5 from baseline values with at least one value > or = 12. Controls (n = 683) were men who reported no BPH treatment or IPSS values >7 over the 7-year trial. Baseline serum was analyzed for C-reactive protein, tumor necrosis factor alpha (monomer), soluble tumor necrosis factor receptors I and II (sTNF-RI and sTNF-RII), interleukin 6, and interferon gamma. Controlled for age and race, a high C-reactive protein concentration was associated with increased BPH risk (for quartile 4 vs. quartile 1, odds ratio (OR) = 1.40, 95% confidence interval (CI): 1.04, 1.88); this was attenuated after control for body mass index (OR = 1.30, 95% CI: 0.95, 1.75). Low sTNF-RII and high interleukin 6 concentrations were associated with increased BPH risk (for quartile 4 vs. quartile 1, sTNF-RII: OR = 0.61, 95% CI: 0.46, 0.82; interleukin 6: OR = 1.79, 95% CI: 1.32, 2.42); these associations were only in men aged <65 years. Results suggest that systemic inflammation or lower levels of soluble receptors that bind inflammatory cytokines increase BPH risk. SN - 1476-6256 UR - https://www.unboundmedicine.com/medline/citation/20142396/Biomarkers_of_systemic_inflammation_and_risk_of_incident_symptomatic_benign_prostatic_hyperplasia:_results_from_the_prostate_cancer_prevention_trial_ L2 - https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwp406 DB - PRIME DP - Unbound Medicine ER -